Tetrandrine differentially inhibits aggregation and ATP-release of rat platelets

Acta Pharmacologica Sinica

Volumn 17, Issue 2, 1996, Pages 105-108

  Chen, Yi Yue ^a,c   Kwan, Chiu Yin ^b   Hui, Siu Chun ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

calcimycin; platelet aggregation; ristocetin; tetrandrine

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ARACHIDONIC ACID; CALCIMYCIN; CALCIUM; CALCIUM ANTAGONIST; CALCIUM IONOPHORE; COLLAGEN; CYCLOPIAZONIC ACID; RISTOCETIN; TETRANDRINE; THROMBIN;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; GEL FILTRATION; MALE; NONHUMAN; RAT; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION;

ADENOSINE TRIPHOSPHATE; ALKALOIDS; ANIMALS; BENZYLISOQUINOLINES; BLOOD PLATELETS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030012325     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Fang DC, Jiang MX. Studies on tetrandrine calcium antagonistic action. Chin Med J 1986; 99: 638-44.
2. King VF, Garcia ML, Himmel D, Reuben JP, Lam YKT, Pan JX, et al. Interaction of tetrandrine with slowly inactivating calcium channels. Characterization of calcium channel modulation by an alkaloid of Chinese medicinal herb origin. J Biol Chem 1988; 263: 2238-44.
3. Gao Y, Chang MY, Mao HY, Chao HY, Chen DH. The clinical observation of tetrandrine in the treatment of 270 cases of hypertensive patients and hypertensive crisis. Chin J Intern Med 1965; 13: 504-8.
4. Kwan CY, Wang ZL. Tetrandrine: a vasodilator of medicinal herb origin with a novel contractile effect on dog saphenous vein. Eur J Pharmacol 1993; 238: 431-4.
5. Chen YY, Lu FH. The interaction between tetrandrine, calcium ion and cardiac glycosides on various heart preparations. Acta Acad Med Wuhan 1983; 3: 123-5.
6. Teh BC, Ioannoni B, Seow WK, McCormack JG, Thong YH. Suppression by tetrandrine of human platelet aggregation induced by platelet-activating factor and other stimulants. Int Arch Allergy Appl Immunol 1989; 88: 267-72.
7. Felix JP, King VF, Shevell JL, Garcia ML, Kaczorowski GJ, Bick IRC, et al. Bis(benzylisoquinoline) analogs of tetrandrine block L-type calcium channels: evidence for interaction at the diltiazem-binding site. Biochemistry 1992; 31: 11793-800.
8. 2 in rabbit platelets. Biochem Pharmacol 1991; 41: 419-23.
9. Kwan CY, Deng HW, Guan YY. Tetrandrine is not a selective calcium channel blocker in vascular smooth muscle. Acta Pharmacol Sin 1992; 13: 385-90.
10. Magocsi M, Sarkadi B, Kovacs T, Gardos G. Thrombin-induced activation of calcium transport pathways and their role in platelet functions. Biochim Biophys Acta 1989; 984: 88-96.
11. Barnathan ES, Addonizio VP, Shattil SJ. Interaction of verapamil with human platelet alpha-adrenergic receptors. Am J Physiol 1982; 242: H19-H23.
12. Lapetina EG. Platelet activating factor stimulates the phosphatidylinositol cycle. J Biol Chem 1982; 257: 7314-7.
13. Darby PJ, Kwan CY, Daniel EE. Use of calcium pump inhibitors in the study of calcium regulation in smooth muscle. Biol Signals 1993; 2: 293-304.
14. Firkin BG. Platelet function. In: Firkin BG, editor. The platelet and its disorder. Hingham: MTP Press, 1984; 37-67.
15. Feinman RD, Detwiler TC. Absence of a requirement for extracellular calcium for secretion from platelets. Thromb Res 1975; 7: 677-9.